STOCK TITAN

Adia Med Partners with Premier FDA-Approved Lab for High-Quality Umbilical Cord Stem Cell and Exosome Products

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership fda approval

Adia (ADIA) has announced a strategic partnership with an FDA-approved laboratory specializing in regenerative medicine. The collaboration focuses on providing high-quality umbilical cord stem cell and exosome products. The lab's products feature 100 million umbilical cord stem cells and 3 trillion exosomes per dose.

The partnership highlights several key attributes: FDA approval ensuring safety and quality protocols for biologics, third-party verification for product quality, minimal manipulation techniques to preserve therapeutic properties, and research excellence in identifying optimal umbilical cord stem cell sources. The products are intended for various therapeutic applications, including orthopedics, neurology, and dermatology.

The company aims to distribute these advanced products for clinical trials, therapeutic use, and preventive medicine applications, particularly in anti-aging and wellness treatments.

Adia (ADIA) ha annunciato una partnership strategica con un laboratorio approvato dalla FDA specializzato in medicina rigenerativa. La collaborazione si concentra sulla fornitura di prodotti di alta qualità a base di cellule staminali del cordone ombelicale e esosomi. I prodotti del laboratorio contengono 100 milioni di cellule staminali del cordone ombelicale e 3 trilioni di esosomi per dose.

La partnership evidenzia diversi attributi chiave: approvazione della FDA che garantisce protocolli di sicurezza e qualità per i prodotti biologici, verifica da parte di terzi per la qualità del prodotto, tecniche di manipolazione minima per preservare le proprietà terapeutiche e eccellenza nella ricerca per identificare le fonti ottimali di cellule staminali del cordone ombelicale. I prodotti sono destinati a varie applicazioni terapeutiche, tra cui ortopedia, neurologia e dermatologia.

L'azienda mira a distribuire questi prodotti avanzati per sperimentazioni cliniche, uso terapeutico e applicazioni di medicina preventiva, in particolare nei trattamenti anti-invecchiamento e di benessere.

Adia (ADIA) ha anunciado una asociación estratégica con un laboratorio aprobado por la FDA especializado en medicina regenerativa. La colaboración se centra en proporcionar productos de alta calidad a base de células madre del cordón umbilical y exosomas. Los productos del laboratorio cuentan con 100 millones de células madre del cordón umbilical y 3 billones de exosomas por dosis.

La asociación destaca varios atributos clave: aprobación de la FDA que garantiza protocolos de seguridad y calidad para biológicos, verificación de terceros para la calidad del producto, técnicas de manipulación mínima para preservar las propiedades terapéuticas y excelencia en la investigación para identificar las fuentes óptimas de células madre del cordón umbilical. Los productos están destinados a diversas aplicaciones terapéuticas, incluyendo ortopedia, neurología y dermatología.

La empresa tiene como objetivo distribuir estos productos avanzados para ensayos clínicos, uso terapéutico y aplicaciones de medicina preventiva, particularmente en tratamientos antienvejecimiento y de bienestar.

Adia (ADIA)는 재생 의학 전문의 FDA 승인 실험실과 전략적 파트너십을 발표했습니다. 이 협력은 고품질 제대혈 줄기 세포 및 엑소좀 제품 제공에 중점을 두고 있습니다. 실험실의 제품은 제대혈 줄기 세포 1억 개와 엑소좀 3조 개를 용량당 함유하고 있습니다.

파트너십은 여러 주요 속성을 강조합니다: 생물학적 제품의 안전성과 품질 프로토콜을 보장하는 FDA 승인, 제품 품질에 대한 제3자 검증, 치료적 특성을 보존하는 최소한의 조작 기술 및 최적의 제대혈 줄기 세포 출처를 식별하는 연구 우수성. 이 제품들은 정형외과, 신경학 및 피부과를 포함한 다양한 치료적 응용을 위해 설계되었습니다.

회사는 이러한 고급 제품을 임상 시험, 치료적 사용 및 예방 의학 응용을 위해 배포할 계획이며, 특히 노화 방지 및 웰빙 치료에 중점을 두고 있습니다.

Adia (ADIA) a annoncé un partenariat stratégique avec un laboratoire approuvé par la FDA spécialisé dans la médecine régénérative. La collaboration se concentre sur la fourniture de produits de haute qualité à base de cellules souches de cordon ombilical et d'exosomes. Les produits du laboratoire contiennent 100 millions de cellules souches de cordon ombilical et 3 trillions d'exosomes par dose.

Le partenariat met en avant plusieurs attributs clés : l'approbation de la FDA garantissant des protocoles de sécurité et de qualité pour les biologiques, la vérification par des tiers de la qualité des produits, des techniques de manipulation minimale pour préserver les propriétés thérapeutiques et l'excellence en recherche pour identifier les sources optimales de cellules souches de cordon ombilical. Les produits sont destinés à diverses applications thérapeutiques, y compris l'orthopédie, la neurologie et la dermatologie.

L'entreprise vise à distribuer ces produits avancés pour des essais cliniques, un usage thérapeutique et des applications de médecine préventive, en particulier dans les traitements anti-âge et de bien-être.

Adia (ADIA) hat eine strategische Partnerschaft mit einem von der FDA zugelassenen Labor für regenerative Medizin angekündigt. Die Zusammenarbeit konzentriert sich auf die Bereitstellung hochwertiger Produkte aus Nabelschnur-Stammzellen und Exosomen. Die Produkte des Labors enthalten 100 Millionen Nabelschnur-Stammzellen und 3 Billionen Exosomen pro Dosis.

Die Partnerschaft hebt mehrere wichtige Merkmale hervor: FDA-Zulassung, die Sicherheits- und Qualitätsprotokolle für Biologika gewährleistet, Drittanbieterüberprüfung der Produktqualität, minimale Manipulationstechniken zur Erhaltung therapeutischer Eigenschaften und Forschungsexzellenz bei der Identifizierung optimaler Nabelschnur-Stammzellquellen. Die Produkte sind für verschiedene therapeutische Anwendungen bestimmt, darunter Orthopädie, Neurologie und Dermatologie.

Das Unternehmen hat sich zum Ziel gesetzt, diese fortschrittlichen Produkte für klinische Studien, therapeutische Anwendungen und präventive Medizin, insbesondere in der Anti-Aging- und Wellnessbehandlung, zu vertreiben.

Positive
  • Partnership with FDA-approved laboratory enhances product credibility and market access
  • High concentration product offering: 100 million stem cells and 3 trillion exosomes per dose
  • Broad therapeutic applications across multiple medical fields
  • Third-party verification ensures product quality and reliability
Negative
  • No immediate revenue projections or financial terms disclosed
  • Market penetration timeline and distribution strategy not specified

Winter Park, Florida--(Newsfile Corp. - February 18, 2025) - Adia (OTC Pink: ADIA) Med is proud to announce a strategic partnership with an FDA-approved laboratory in the field of regenerative medicine. This collaboration marks a new era in the availability of top-tier, third-party verified, and minimally manipulated umbilical cord stem cell and exosome products.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/241216_stem-cell-lab_550.jpg

Adia Med Partners with Premier FDA-Approved Lab for High-Quality Umbilical Cord Stem Cell and Exosome Products

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/241216_stem-cell-lab.jpg

Following exhaustive research, Adia Med has selected this lab for its unparalleled expertise and compliance with the highest regulatory standards. The lab's commitment to quality, safety, and innovation has been crucial in ensuring that Adia Med can offer products that meet the stringent demands of medical professionals and patients alike.

CEO of Adia Nutrition, Larry Powalisz stated, "After months of due diligence and building strategic relationships within our medical niche, I can with unreserved confidence say that not only do we offer the best quality therapies but also the best quantities per treatment."

Key Attributes of Our Lab Partner:

  • FDA Approval: The laboratory has achieved FDA approval, underscoring its adherence to rigorous safety and quality protocols for biologics.

  • Quality Assurance: All products undergo third-party verification, ensuring that each batch of stem cells and exosomes is of the highest purity, potency, and viability.

  • Minimal Manipulation: The lab's techniques are designed to preserve the natural state and therapeutic properties of the cells, offering minimally manipulated products that are both effective and safe.

  • Research Excellence: Known for its groundbreaking research, the lab has been instrumental in pinpointing the best sources for umbilical cord stem cells, which are celebrated for their high regenerative potential and low risk of rejection.

  • Broad Therapeutic Applications: The partnership will enable the distribution of these advanced products, which hold promise for applications in orthopedics, neurology, dermatology, and more.

Dr. Monica Sher, director of Umbilical Cord Stem Cell (UCB-SC) Treatments at Adia Med, expressed enthusiasm about the partnership, stating, "Our collaboration with this exceptional lab is a testament to our dedication to excellence in regenerative medicine. Their reputation for quality and compliance with FDA standards ensures that we can offer the best possible products to the medical community."

Following rigorous research into the sourcing and optimization of umbilical cord stem cells, Adia Med has identified what they believe to be the most potent and pure stem cells available. The lab has formulated a product with an unprecedented concentration of 100 million umbilical cord stem cells and 3 trillion exosomes per dose, designed to maximize therapeutic impact for a wide range of conditions.

Key Applications:

  • Clinical Trials: Researchers will have access to a consistent, high-quality source of stem cells and exosomes for studying regeneration and repair mechanisms.

  • Therapeutic Use: The product is poised for use in treatments aimed at conditions ranging from orthopedic injuries to neurodegenerative diseases, where stem cell therapy can offer non-invasive, regenerative solutions.

  • Preventive Medicine: Potential applications in anti-aging and wellness, leveraging the regenerative properties of stem cells and exosomes.

Adia Med is committed to ensuring this premium product reaches healthcare providers who are at the forefront of regenerative medicine. Clinicians interested in this new offering can find more information or engage in partnerships by visiting Adia Med's official website (adiamed.com) or contacting their support team.

For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com

Website: www.adia-med.com

Website: www.biolete.com

Website: www.cementfactory.co

Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/241216

FAQ

What is the concentration of stem cells and exosomes in ADIA's new product?

ADIA's new product contains 100 million umbilical cord stem cells and 3 trillion exosomes per dose.

What therapeutic applications will ADIA's stem cell products target?

The products will target applications in orthopedics, neurology, dermatology, anti-aging, and wellness treatments.

How does ADIA ensure the quality of its stem cell products?

ADIA ensures quality through FDA approval, third-party verification, and minimal manipulation techniques to preserve therapeutic properties.

When did ADIA announce its partnership with the FDA-approved laboratory?

ADIA announced the partnership on February 18, 2025.

What are the key features of ADIA's laboratory partnership?

The partnership features FDA approval, quality assurance through third-party verification, minimal manipulation techniques, and research excellence in stem cell sourcing.

Adia Nutrition

OTC:ADIA

ADIA Rankings

ADIA Latest News

ADIA Stock Data

5.71M
71.90M
Shell Companies
Financial Services
Link
United States
Kurtistown